{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:15:56Z","timestamp":1769206556068,"version":"3.49.0"},"reference-count":48,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Vifor Fresenius Medical Care Renal Pharma"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2024,2,7]]},"DOI":"10.1080\/14737167.2023.2297790","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T13:43:21Z","timestamp":1703166201000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain"],"prefix":"10.1080","volume":"24","author":[{"given":"Manuel","family":"Mac\u00eda","sequence":"first","affiliation":[{"name":"Nephrology Service, Hospital Universitario Nuestra Se\u00f1ora de Candelaria, Santa Cruz de Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"D\u00edaz-Encarnaci\u00f3n","sequence":"additional","affiliation":[{"name":"Nephrology Service, Fundaci\u00f3 Puigvert, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Solans-Laqu\u00e9","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Valle de Hebr\u00f3n, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisenda Pomares","family":"Mallol","sequence":"additional","affiliation":[{"name":"Market Access, PharmaLex, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra Garc\u00eda","family":"Castells","sequence":"additional","affiliation":[{"name":"Market Access, PharmaLex, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Escribano","sequence":"additional","affiliation":[{"name":"Medical Department, CSL Vifor, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Ram\u00edrez","family":"de Arellano","sequence":"additional","affiliation":[{"name":"HEOR, CSL Vifor, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"issue":"2","key":"e_1_3_7_5_1","first-page":"S","article-title":"Epidemiological study of primary systemic vasculitides among adults in Southern Spain and review of the main epidemiological studies","volume":"33","author":"Romero-G\u00f3mez C","year":"2015","unstructured":"Romero-G\u00f3mez C, Aguilar-Garc\u00eda JA, Garc\u00eda-de-Lucas MD, et al. Epidemiological study of primary systemic vasculitides among adults in Southern Spain and review of the main epidemiological studies. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11115"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006083"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.218"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3973-2"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key260"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00769.x"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203927"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003432"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764"},{"key":"e_1_3_7_16_1","unstructured":"European Medicines Agency. Avacopan SmPC; 2022 [cited 2022 Dec 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tavneos-epar-product-information_en.pdf"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386"},{"key":"e_1_3_7_18_1","unstructured":"National Institute for Health and Care Excellence. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [Internet]. 2022 [cited 2022 Dec 9]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta825"},{"key":"e_1_3_7_20_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Avacopan Tavneos 10mg capsuse first assessment adopted by the Transparency Committee on 21 September 2022. 2022."},{"key":"e_1_3_7_21_1","unstructured":"Ministerio de Sanidad. Puntos destacados de la reuni\u00f3n de la Comisi\u00f3n Interministerial de Precios de los Medicamentos - 15 de junio de 2023 [Internet]. 2023 [cited 2023 Jul 18]. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/NOTAINFORMATIVACIPM_JUNIO23.pdf"},{"key":"e_1_3_7_22_1","unstructured":"Ortega Eslava A Mar\u00edn Gil R Fraga Fuentes MD et al. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos [Internet]. 2016 [cited 2023 Aug 11]. Available from: https:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Documents\/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.09.022"},{"key":"e_1_3_7_25_1","unstructured":"Instituto Nacional de Estad\u00edstica. Tablas de mortalidad por a\u00f1o sexo edad y funciones. [Internet]. 2022 [cited 2022 Jul 25]. Available from: https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=27153"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.07.009"},{"key":"e_1_3_7_27_1","unstructured":"UK Renal Registry. UK renal registry 23rd annual report \u2013 data to 31\/12\/2019 [Internet]. Bristol (UK); 2021 [cited 2022 Dec 9]. Available from: https:\/\/ukkidney.org\/sites\/renal.org\/files\/23rd_UKRR_ANNUAL_REPORT.pdf"},{"key":"e_1_3_7_28_1","unstructured":"Ministerio de Sanidad. Portal Estad\u00edstico del SNS - Registro de Altas de los Hospitales del Sistema Nacional de Salud. CMBD [Internet]. 2022 [cited 2022 Jul 26]. Available from: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/cmbdhome.htm"},{"key":"e_1_3_7_29_1","unstructured":"Gisbert R Brosa M. Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud [Internet]. 2007 [cited 2022 Apr 12]. Available from: http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"e_1_3_7_30_1","unstructured":"Alianza frente a la Poliquistosis Renal Autos\u00f3mica Dominante. Libro Blanco de la Poliquistosis Renal Autos\u00f3mica Dominante (PQRAD) en Espa\u00f1a [Internet]. 2016 [cited 2023 Aug 11]. Available from: https:\/\/senefro.org\/contents\/webstructure\/noticias\/LIBRO_PQRAD.pdf"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recote.2018.11.004"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-315"},{"key":"e_1_3_7_33_1","unstructured":"Consejer\u00edas de Sanidad de las Comunidades Aut\u00f3nomas. Documento Marco sobre Enfermedad Renal Cr\u00f3nica (ERC) dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. 2015 [cited 2023 Aug 11]. Available from: https:\/\/www.sanidad.gob.es\/organizacion\/sns\/planCalidadSNS\/pdf\/Enfermedad_Renal_Cronica_2015.pdf"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1131-3587(13)70079-7"},{"key":"e_1_3_7_35_1","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Portal Farma. BotPLUS [Internet]. 2023 [cited 2023 Aug 10]. Available from: https:\/\/botplusweb.portalfarma.com\/botplus.aspx"},{"key":"e_1_3_7_36_1","unstructured":"Ministerio de Sanidad. Listado de medicamentos afectados por las deducciones del Real Decreto-Ley 8\/2010. Septiembre 2023 [Internet]. 2023 [cited 2023 Sep 10]. Available from: https:\/\/www.sanidad.gob.es\/en\/areas\/farmacia\/infoIndustria\/infoDeducciones\/ley8_2010\/docs\/Deducciones_Septiembre_23.pdf"},{"key":"e_1_3_7_37_1","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta Nacional de Salud (ENSE); 2017 [cited 2023 Aug 11]. Available from: https:\/\/www.ine.es\/"},{"key":"e_1_3_7_38_1","unstructured":"National Institute for Health and Care Excellence. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody associated vasculitis [Internet]. 2014 [cited 2023 Aug 11]. Available from: https:\/\/www.nice.org.uk\/Guidance\/TA308"},{"key":"e_1_3_7_39_1","unstructured":"National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia [internet]. 2020 [cited 2023 Aug 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA623"},{"key":"e_1_3_7_40_1","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta Nacional de Salud (ENSE) 2011 [Internet]. 2011 [cited 2023 Aug 11]. Available from: https:\/\/www.ine.es\/"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2019.06.007"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa073"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92629-7"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131038"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641655"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00025-8"},{"key":"e_1_3_7_48_1","unstructured":"Powell T O\u2019Donell M. NICE appraisals of rare diseases [internet]. House Of Commons Library. 2019 [cited 2023 Aug 11]. Available from: https:\/\/researchbriefings.files.parliament.uk\/documents\/CDP-2019-0022\/CDP-2019-0022.pdf"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1330152"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.628"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.760"},{"key":"e_1_3_7_52_1","first-page":"1759","volume-title":"2017 ACR\/ARHP Annual Meeting","author":"Montante A","year":"2017","unstructured":"Montante A, Le Bras A, Terrier B, et al. Economic evaluation of rituximab versus azathioprine for maintenance treatment of ANCA-associated vasculitis. A prospective, multicenter study. 2017 ACR\/ARHP Annual Meeting; Nov 3\u20138; San Diego, CA; 2017. Abstract number: 1759."}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2297790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:53:53Z","timestamp":1727218433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2297790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,7]]}},"alternative-id":["10.1080\/14737167.2023.2297790"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2297790","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}